Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1624-1632

  Huang, Xiaoyuan ^a   Zhuang, Liang ^a   Cao, Yang ^a   Gao, Qinglei ^a   Han, Zhiqiang ^a   Tang, Duozhuang ^a   Xing, Hui ^a   Wang, Wei ^a   Lu, Yunping ^a   Xu, Gang ^a   Wang, Shixuan ^a   Zhou, Jianfeng ^a   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS M1; POLO LIKE KINASE 1; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; ONCOLYTIC VIRUS; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS INHIBITION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL TIME; TISSUE DISTRIBUTION; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; ENZYMOLOGY; KAPLAN MEIER METHOD; KINETICS; METABOLISM; METASTASIS; NECROSIS; PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR; TIME; VIROLOGY;

ADENOVIRIDAE; ANIMALS; CELL CYCLE PROTEINS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KINETICS; MICE; MICE, INBRED BALB C; NECROSIS; NEOPLASM METASTASIS; ONCOLYTIC VIRUSES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; STOMACH NEOPLASMS; TIME FACTORS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49849089090     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2134     Document Type: Article

References (32)

1. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000;19:6660-9.
2. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000;6:3395-9.
3. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24:7802-16.
4. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9.
5. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98.
6. Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther 2003;14:425-33.
7. Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, Wildner O. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol 2006;80:3549-58.
8. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
9. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50.
10. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005;12:141-61.
11. Le LP, Le HN, Dmitriev IP, et al. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst 2006;98:203-14.
12. Zhou J, Gao Q, Chen G, et al. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res 2005;11:8431-40.
13. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995;3:207-20.
14. Motoyama T, Hojo H, Watanabe H. Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn 1986;36:65-83.
15. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther 2005;16:664-77.
16. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007;109:2832-9.
17. Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther 2001;8:1123-31.
18. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005;8:61-74.
19. Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther 2005;5:429-43.
20. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60:6359-66.
21. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9.
22. Tsai V, Johnson DE, Rahman A, et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004;10:7199-206.
23. Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 2004;64:3281-7.
24. Ryan PC, Jakubczak JL, Stewart DA, et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004;11:555-69.
25. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 2001;61:3501-7.
26. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002;13:485-95.
27. Ganly I, Kim YT, Hann B, Balmain A, Brown R. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene Ther 2001;8:369-75.
28. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
29. Min Y, Adachi Y, Yamamoto H, et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005;54:591-600.
30. Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 2007;13:341-9.
31. White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001;20:7836-46.
32. Stiewe T, Parssanedjad K, Esche H, Opalka B, Putzer BM. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Cancer Res 2000;60:3957-64.